Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 6/20 | 0.39 |
| ▸ | ACACB | O00763 | 3/20 | 0.37 |
| ▸ | ACACA | Q13085 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 4/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19429836 | 0.86 | AOC3 (0.35) | AOC3ACACBACACACYP1A2CYP3A4 | |
| SCHEMBL19430088 | 0.86 | AOC3 (0.35) | AOC3ACACBACACACYP1A2CYP3A4 | |
| SCHEMBL19430363 | 0.86 | AOC3 (0.35) | AOC3ACACBACACACYP1A2CYP3A4 | |
| SCHEMBL19430062 | 0.86 | AOC3 (0.40) | AOC3MTORPRMT6KMT2A | |
| SCHEMBL19429824 | 0.86 | AOC3 (0.43) | AOC3MTORPRMT6NAPEPLDKMT2A | |
| SCHEMBL19430193 | 0.86 | AOC3 (0.37) | AOC3ACACBACACACYP1A2CYP3A4 | |
| SCHEMBL19430181 | 0.86 | AOC3 (0.38) | AOC3PRMT6KMT2A | |
| SCHEMBL19429847 | 0.85 | HTT (0.37) | AOC3 | |
| SCHEMBL19429904 | 0.85 | KLKB1 (0.39) | AOC3CYP2C9WDR5ALDH1A1 | |
| SCHEMBL19430013 | 0.85 | AOC3 (0.37) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | AOC3 2654/4885ACACB 1192/4885ACACA 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.